Envestnet Portfolio Solutions increased its holdings in Eli Lilly and Company during Q2, reflecting strong institutional confidence following impressive earnings and significant strategic investments in manufacturing and pipeline development.
Envestnet Portfolio Solutions increased its holding in Eli Lilly and Company during the second quarter, adding 2,976 shares and lifting its stake by 7.7%, according to a filing with the Securities and Exchange Commission. The firm ended the period with 41,689 shares worth about $49.99 million, underscoring the continued institutional appetite for the drugmaker’s stock even after a strong run-up this year.
The move came amid broad buying from large investors. MarketBeat’s reporting on recent filings shows that BlackRock, State Street, Capital World Investors, Norges Bank and Bank of America’s brokerage arm all maintained sizeable positions in Lilly, while UNIVEST Financial and the National Pension Service also expanded their holdings. Together, institutional investors and hedge funds now control about 82.5% of the company’s shares, a level that points to deep support from professional money managers even as valuation remains elevated.
Eli Lilly’s latest results have helped explain that enthusiasm. The company reported second-quarter earnings per share of $8.38, well ahead of the $6.40 forecast, on revenue of $22.97 billion, which was up 47.7% from a year earlier. Lilly kept its fiscal 2026 earnings guidance at $35.50 to $36.50 a share, after previously raising the range earlier in the year. Analysts remain broadly positive, with MarketBeat putting the consensus at a Moderate Buy and an average target price around $1,295.25.
At the same time, Lilly’s premium valuation and the competitive battle in obesity medicines continue to attract scrutiny. The stock recently traded near $1,153.69, giving the company a market value of roughly $1.09 trillion and a price-to-earnings ratio of 38.71. Insider sales have added to the caution for some investors, including transactions by chief accounting officer Donald Zakrowski and executive vice-president Patrik Jonsson in August.
Beyond the quarter’s numbers, Lilly is also pressing ahead with major strategic investments. The company has broken ground on a $6.5 billion manufacturing site in Houston that is expected to support production for its oral GLP-1 medicines and create more than 600 jobs. The company is also advancing its broader pipeline, including a recent full approval for Inluriyo in combination with Verzenio for advanced ESR1-mutated breast cancer. Still, the commercial outlook for Lilly’s obesity franchise is not without risk, with competing data from Viking Therapeutics and Novo Nordisk keeping pressure on the sector.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
